Oneness Biotech Co., Ltd. (LUX:ONEA)
Luxembourg flag Luxembourg · Delayed Price · Currency is EUR · Price in USD
10.60
-0.20 (-1.85%)
At close: Jul 31, 2025

Oneness Biotech Company Description

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan.

It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.

It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases.

In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products.

Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

Oneness Biotech Co., Ltd.
CountryTaiwan
Founded2008
IndustryBiological Products, Except Diagnostic Substances
Employees43
CEOShuling Cheng

Contact Details

Address:
No. 66, Zhonzheng W. Rd.
Taipei, 100
Taiwan
Phone886 2 2703 1098
Websiteonenessbio.com

Stock Details

Ticker SymbolONEA
ExchangeLuxembourg Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyTWD
SIC Code2836

Key Executives

NamePosition
Shuling ChengChief Executive Officer
Ting-Fang ChenChief Financial Officer